Navigation Links
Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
Date:10/26/2010

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at Oppenheimer's 21st Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, November 2, 2010, at 10:15 a.m. Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcast of this presentation will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of this presentation will be available at the same location for 30 days after the presentation.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA to the EMA (Europe) for fidaxomicin.  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. We plan to have an NDA submitted to the FDA in the first quarter of 2011.
Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer &
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
2. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
3. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
4. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
8. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
9. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
10. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
11. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 01, 2015 Park Systems, ... selected to receive the prestigious “Best Analytic Instrumentation ... NX10 is the premium research-grade True Non-Contact AFM, ... linearity, closed-loop detector noise, and minimized thermal drift. ... n, which allows images with a single click, ...
(Date:4/1/2015)... April 1, 2015  VLP Therapeutics, LLC. ("VLP"), a ... the research and development of therapeutic and preventative vaccines ... and proprietary vaccine technology, today announced that it has entered ... Medicine at Nagasaki University in ... VLP,s research and development of dengue vaccine candidates. ...
(Date:4/1/2015)... 1, 2015  ValGenesis Inc., the market leader in ... it has completed its Service Organization Controls 2 (SOC ... Professional Standards) for the period of January 1 st ... Logo - ... The SOC 2 examination is performed ...
(Date:4/1/2015)... 1, 2015 Goldman Small Cap Research, a ... and microcap sectors, announced today that it has issued ... PMCB), a publicly traded clinical stage biotechnology company focused ... To view the sponsored research article, along with disclosures ... please visit www.GoldmanResearch.com .  In ...
Breaking Biology Technology:Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4
... Expanded Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... Inc., a life,sciences company developing revolutionary bench-top flow cytometer ... C financing led by,Fidelity Biosciences and Flagship Ventures. Current ...
... Mich., July 8 GeneGo, Inc., the leading,systems ... Center,at Yale has become a certified GeneGo Center ... GeneGo,s MetaCore, training and advanced,support., The W. ... of the largest biotechnology laboratories of its kind ...
... TechCFO, a leading provider of outsourced CFO-level financial and management services ... Strickland as Partner to its Boston office. Strickland is the latest ... of last year. , ... Cambridge, MA (PRWEB) July ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2TechCFO Adds Gary Strickland as Partner in Boston Office 2
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... for some time that exercise induces neurogenesis in a ... the underlying mechanism was not fully understood. The hippocampus ... and is one of the brain regions where new ... precursor cell maturation , The researchers demonstrated that ...
... described as "orphan diseases, too small to be noticed, ... Lorenzo,s Oil, rare diseases are getting unprecedented attention today ... and marketing new medicines that promise fuller lives for ... That,s the finding of a major examination, published today ...
... at protecting leaves from being chomped by slugs, suggests research ... Although they lurk in the soil, they seem to protect ... amount of damage slugs do to individual plants. Spanish ... worst alien species in Europe and are considered a pest ...
Cached Biology News:Serotonin mediates exercise-induced generation of new neurons 2Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 2Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 3Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 4Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 5
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
... PS10 ProteinChip Arrays are preactivated with carbonyl ... primary amine groups. The PS10 array contains ... PS1 array, but with an updated hydrophobic ... chips with 2 mm diameter spots spatially ...
...
Biology Products: